The Pectoralis (PECS2) Block Versus Intrathecal Morphine
NCT ID: NCT06016205
Last Updated: 2023-09-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
50 participants
INTERVENTIONAL
2023-12-01
2024-09-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Direct Versus US Guided PECS Block on Controlling Postmastectomy Pain
NCT05825430
Comparing Post-operative Analgesia After (PECS II) Block and (ESPB) in Modified Radical Mastectomy
NCT06714682
PECS II vs. MTP for Analgesia After MRM
NCT06187909
Comparative Study Between Combined Modified Pectoral Nerve Block (PECSΙΙ) and Transversus Thoracic Plane Block Versus Erector Spinae Plane Block for Post-operative Analgesia Following Breast Surgeries, (randomized Clinical Trial Study)
NCT06783764
Modified Pectoral Nerve Block Vs Thoracic Erector Spinae Plane Block for Analgesia for Aesthetic Breast Surgeries
NCT06478654
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
morphine group (n=25):
Patients will receive intrathecal 200 microgram morphine immediately before induction of general anesthesia.
PECS group (n= 25):
PECS2 block will be performed and Patients will receive 30 ml bupivacaine 0.25% The drug solutions will be prepared by an anesthesiologist not involved in the study, the anesthesiologist performing the block and observing the patients will be blinded to the treatment group. Data collection will be done by anesthesiologist unaware of the group allocation.
In the PECS group patients will be placed in supine position. The block will be performed on the side of surgery with the ipsilateral upper limb in abduction position. After the skin of the infraclavicular region disinfected and preparing the US probe and adjusting the depth of 4 to 6cm and gain of Ultrasound machine .The 20-gauge echogenic needle will be introduced in-plane approach from medial to lateral and 10ml of bupivacaine 0.25% will be injected into the fascial plane between pectoralis muscles in order to block medial and lateral pectoral nerve (PECS I). Then the needle will be reinserted into the fascial plane between pectoralis minor and serratus anterior muscle and 20ml of bupivacaine 0.25%will be injected in increments of 5 ml after negative aspiration in order to block intercostals II-III-IV-V-VI and the long thoracic nerve.
General anesthesia will be induced in all patients with fentanyl (1-2ug/kg), propofol (1-2mg/kg) and an intuitive dose of atracurium (0. 5mg/kg), endotracheal intubation secured the airway. Anesthesia will be maintained with isoflurane (1- 2%) and an incremental dose of atracurium 0.1mg/kg. Controlled ventilation will be accomplished by a ventilator with a tidal volume of 6-8 ml/kg and an I/E ratio of 1:2 to maintain a tidal carbon dioxide voltage of approximately 35-40 mmHg.
The heart rate (HR), noninvasive arterial systolic blood pressure (SBP), diastolic blood pressure (DBP) and peripheral oxygen saturation (SpO2) will be recorded at baseline, after induction and with skin incision and every 5 minutes intraoperative till the end of surgery. And postoperative at 30 min, 1, 2, 3, 6, 12 and 24 hours.
\- Postoperative pain will be assessed using visual analog score (VAS) \[0-10\]. 0 - 3 mild pain
* 4 - 6 moderate pain
* 7 - 10 severe pain
* 10 \<unbearable pain)
All patients will receive paracetamol (1gm) immediately postoperative and every 6 hours. Patients will be assessed every one hour in the first 6 hours then every 4 hours in the next 18 hours. Patients will receive ketorolac 30 mg if VAS 3-5. If VAS\>5, morphine 0.1mg/kg will be given then total ketorolac and morphine consumption in 24 hours will be calculated and compared between both groups.
Adverse effects will be considered as -bradycardia (if heart rate \[HR\] is \<20% of baseline) will be treated by atropine (IV) 0.01 mg/kg.
* Hypotension (if mean arterial blood pressure is \<20% of baseline) will be treated with (IV) fluid and an incremental (IV) dose of ephedrine 0.2- 0.3 mg/kg or (SC/IM) dose of ephedrine 0.5 mg/kg.
* Respiratory depression, apnea and hypoxemia (spo2 \< 92%) will be treated with O2 supplementation.
* Also, complications as disturbed conscious level, nausea, vomiting and prolonged motor block will be recorded.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
HEALTH_SERVICES_RESEARCH
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Morphine group (n= 25):
intrathecal morphine injection
Patients will receive intrathecal 200 microgram morphine immediately before induction of general anesthesia
PECS group (n= 25):
ultrasound guided PECS2 block
ultrasound guided PECS2 block will be performed with 30 ml bupivacaine 0.25%
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
intrathecal morphine injection
Patients will receive intrathecal 200 microgram morphine immediately before induction of general anesthesia
ultrasound guided PECS2 block
ultrasound guided PECS2 block will be performed with 30 ml bupivacaine 0.25%
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Patient with significant neurological , psychiatric or neuromuscular disease
* Alcoholism. Drug abuse.
* Pregnancy or lactating women.
* Suspected Coagulopathy.
* Morbid obesity.
* Known allergy to study medications.
* local infection at the block site
18 Years
60 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sohag University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Mohammed Ahmed Mahmoud
Lecturer of anesthesia and ICU
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sohag University
Sohag, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Soh-Med-22-07-33
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.